Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study

Imagem de Miniatura
Arquivos
art_BRONSTEIN_Switching_patients_with_acromegaly_from_octreotide_to_pasireotide_2016.PDF (725.63 KB)
Citações na Scopus
63
Tipo de produção
article
Data de publicação
2016
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
BIOMED CENTRAL LTD
Autores
FLESERIU, Maria
NEGGERS, Sebastian
COLAO, Annamaria
SHEPPARD, Michael
GU, Feng
SHEN, Chiung-Chyi
GADELHA, Monica
FARRALL, Andrew J.
RESENDIZ, Karina Hermosillo
Citação
BMC ENDOCRINE DISORDERS, v.16, article ID 16, 10p, 2016
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Many patients with acromegaly do not achieve biochemical control with first-generation somatostatin analogues. A large, multicenter, randomized, Phase III core study demonstrated that pasireotide LAR had significantly superior efficacy over octreotide LAR. This analysis explores the efficacy and safety of switching therapeutic arms in inadequately controlled patients during a 12-month crossover extension. Methods: Patients with inadequate biochemical control (GH >= 2.5 mu g/L and/or IGF 1 > ULN) at end of core study (month 12) were eligible to switch to pasireotide LAR 40 mg/28 days (n = 81) or octreotide LAR 20 mg/28 days (n = 38). One dose escalation to pasireotide LAR 60 mg/28 days or octreotide LAR 30 mg/28 days was permitted, but not mandatory, at month 17 or 20. Results: Twelve months after crossover, 17.3 % of pasireotide LAR and 0 % of octreotide LAR patients achieved GH <2.5 mu g/L and normal IGF-1 (main outcome measure); 27.2 and 5.3 % of pasireotide LAR and octreotide LAR patients achieved normal IGF-1, respectively; 44.4 and 23.7 % of pasireotide LAR and octreotide LAR patients achieved GH < 2.5 mu g/L, respectively. Mean (+/- SD) tumor volume further decreased from the end of the core study by 25 % (+/- 25) and 18 % (+/- 28); 54.3 % of pasireotide LAR and 42.3 % of octreotide LAR patients achieved significant (>= 20 %) tumor volume reduction during the extension. The safety profile of pasireotide LAR was similar to that of octreotide LAR, with the exception of the frequency and degree of hyperglycemia-related adverse events. Conclusions: Pasireotide LAR is a promising treatment option for patients with acromegaly inadequately controlled with the first-generation somatostatin analogue octreotide LAR.
Palavras-chave
Pasireotide, Octreotide, Acromegaly, Extension, Crossover
URI
https://observatorio.fm.usp.br/handle/OPI/14452
Referências
  1. Melmed S, 2009, J CLIN ENDOCR METAB, V94, P1509, DOI 10.1210/jc.2008-2421
  2. Henry RR, 2013, J CLIN ENDOCR METAB, V98, P3446, DOI 10.1210/jc.2013-1771
  3. Webb SM, 2002, CLIN ENDOCRINOL, V57, P251, DOI 10.1046/j.1365-2265.2002.01597.x
  4. Holdaway IM, 2008, EUR J ENDOCRINOL, V159, P89, DOI 10.1530/EJE-08-0267
  5. Sheppard M, 2015, PITUITARY, V18, P385, DOI 10.1007/s11102-014-0585-6
  6. Katznelson L, 2014, J CLIN ENDOCR METAB, V99, P3933, DOI 10.1210/jc.2014-2700
  7. Giustina A, 2010, J CLIN ENDOCR METAB, V95, P3141, DOI 10.1210/jc.2009-2670
  8. Neggers SJCMM, 2014, J CLIN ENDOCR METAB, V99, P3644, DOI 10.1210/jc.2014-2032
  9. Murray RD, 2004, J CLIN INVEST, V114, P349, DOI 10.1172/jci200419933
  10. Colao A, 2014, PITUITARY, V17, P180, DOI 10.1007/s11102-013-0483-3
  11. Colao A, 2011, ENDOCR REV, V32, P247, DOI 10.1210/er.2010-0002
  12. Cuevas-Ramos D, 2014, J MOL ENDOCRINOL, V52, pR223, DOI 10.1530/JME-14-0011
  13. Neggers SJCMM, 2016, NEUROENDOCRINOLOGY, V103, P59, DOI 10.1159/000381644
  14. Melmed S, 2006, NEW ENGL J MED, V355, P2558, DOI 10.1056/NEJMra062453
  15. Colao A, 2014, J CLIN ENDOCR METAB, V99, P791, DOI 10.1210/jc.2013-2480
  16. Parkinson C, 2002, J CLIN ENDOCR METAB, V87, P1797, DOI 10.1210/jc.87.4.1797
  17. Colao A, 2009, CLIN ENDOCRINOL, V70, P757, DOI 10.1111/j.1365-2265.2008.03441.x
  18. Chanson P, 2008, CLIN ENDOCRINOL, V69, P299, DOI 10.1111/j.1365-2265.2008.03208.x
  19. Melmed S, 2010, PITUITARY, V13, P18, DOI 10.1007/s11102-009-0191-1
  20. Trepp R, 2005, CLIN ENDOCRINOL, V63, P103, DOI 10.1111/j.1365-2265.2005.02307.x
  21. Mercado M, 2007, CLIN ENDOCRINOL, V66, P859, DOI 10.1111/j.1365-2265.2007.02825.x
  22. Giustina A, 2000, J CLIN ENDOCR METAB, V85, P526, DOI 10.1210/jc.85.2.526
  23. Colao A, 2004, ENDOCR REV, V25, P102, DOI 10.1210/er.2002-0022
  24. van der Lely AJ, 2001, LANCET, V358, P1754, DOI 10.1016/S0140-6736(01)06844-1
  25. van der Lely AJ, 2012, J CLIN ENDOCR METAB, V97, P1589, DOI 10.1210/jc.2011-2508
  26. Gadelha MR, 2014, LANCET DIABETES ENDO, V2, P875, DOI 10.1016/S2213-8587(14)70169-X
  27. Giustina A, 2014, NAT REV ENDOCRINOL, V10, P243, DOI 10.1038/nrendo.2014.21
  28. National Cancer Institute, 2006, COMM TERM CRIT ADV E

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/25
Artigos e Materiais de Revistas Científicas - ODS/03